Telix Pharmaceuticals

24/9 update: Gozellix has received US CMS transitional pass-through (TPT) status, effective from 1 Oct-25.
Transitional pass through (TPT) status allows for a separate payment in addition to payment for imaging in the outpatient setting.

22/9 update: Buy with a stop-loss at $14.10

You’re not a member!  Trial today

Telix Pharmaceuticals

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.